TrialBMC nephrology2013

T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease.

Masanori Abe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.